AU2002245329A1 - Degradation-resistant glucocorticosteroid formulations - Google Patents
Degradation-resistant glucocorticosteroid formulationsInfo
- Publication number
- AU2002245329A1 AU2002245329A1 AU2002245329A AU2002245329A AU2002245329A1 AU 2002245329 A1 AU2002245329 A1 AU 2002245329A1 AU 2002245329 A AU2002245329 A AU 2002245329A AU 2002245329 A AU2002245329 A AU 2002245329A AU 2002245329 A1 AU2002245329 A1 AU 2002245329A1
- Authority
- AU
- Australia
- Prior art keywords
- radical quencher
- glucocorticosteroid
- pharmaceutical composition
- formulation
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims description 145
- 238000009472 formulation Methods 0.000 title claims description 124
- 239000003862 glucocorticoid Substances 0.000 title claims description 56
- 230000015556 catabolic process Effects 0.000 title description 26
- 238000006731 degradation reaction Methods 0.000 title description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 63
- 239000006184 cosolvent Substances 0.000 claims description 49
- 239000003380 propellant Substances 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 45
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 34
- 229960004436 budesonide Drugs 0.000 claims description 34
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 24
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 24
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 24
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical group FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims description 20
- 229940071648 metered dose inhaler Drugs 0.000 claims description 20
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 18
- 239000000443 aerosol Substances 0.000 claims description 18
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 17
- 229930003427 Vitamin E Natural products 0.000 claims description 16
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 16
- 235000019165 vitamin E Nutrition 0.000 claims description 16
- 229940046009 vitamin E Drugs 0.000 claims description 16
- 239000011709 vitamin E Substances 0.000 claims description 16
- 229920005862 polyol Polymers 0.000 claims description 15
- 150000003077 polyols Chemical group 0.000 claims description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 14
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 12
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 12
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 12
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 12
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 12
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 12
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 12
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 12
- 238000010525 oxidative degradation reaction Methods 0.000 claims description 10
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 9
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims description 6
- 208000014181 Bronchial disease Diseases 0.000 claims description 6
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims description 6
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 6
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical group CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 6
- 108010024636 Glutathione Proteins 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 6
- 235000010323 ascorbic acid Nutrition 0.000 claims description 6
- 229960005070 ascorbic acid Drugs 0.000 claims description 6
- 239000011668 ascorbic acid Substances 0.000 claims description 6
- 229940092705 beclomethasone Drugs 0.000 claims description 6
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims description 6
- 229960002537 betamethasone Drugs 0.000 claims description 6
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 6
- 235000021466 carotenoid Nutrition 0.000 claims description 6
- 150000001747 carotenoids Chemical class 0.000 claims description 6
- 229960003728 ciclesonide Drugs 0.000 claims description 6
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 6
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 6
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 6
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 claims description 6
- 229960003662 desonide Drugs 0.000 claims description 6
- 229960003957 dexamethasone Drugs 0.000 claims description 6
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 6
- 229940011871 estrogen Drugs 0.000 claims description 6
- 239000000262 estrogen Substances 0.000 claims description 6
- 229960000676 flunisolide Drugs 0.000 claims description 6
- 229960002714 fluticasone Drugs 0.000 claims description 6
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 6
- 235000003969 glutathione Nutrition 0.000 claims description 6
- 229960003180 glutathione Drugs 0.000 claims description 6
- 229960000890 hydrocortisone Drugs 0.000 claims description 6
- 229960004584 methylprednisolone Drugs 0.000 claims description 6
- 229960001664 mometasone Drugs 0.000 claims description 6
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims description 6
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 6
- 229960004618 prednisone Drugs 0.000 claims description 6
- 229960003387 progesterone Drugs 0.000 claims description 6
- 239000000186 progesterone Substances 0.000 claims description 6
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims description 6
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 6
- IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 claims description 6
- 229950004432 rofleponide Drugs 0.000 claims description 6
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 6
- 229960003604 testosterone Drugs 0.000 claims description 6
- 229940042585 tocopherol acetate Drugs 0.000 claims description 6
- 229960005294 triamcinolone Drugs 0.000 claims description 6
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 6
- 229940035936 ubiquinone Drugs 0.000 claims description 6
- 150000003254 radicals Chemical class 0.000 description 45
- 239000000243 solution Substances 0.000 description 20
- 239000003814 drug Substances 0.000 description 17
- 239000012535 impurity Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 239000007857 degradation product Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- 229940124630 bronchodilator Drugs 0.000 description 7
- 239000002904 solvent Substances 0.000 description 6
- -1 HFA- 134a Chemical compound 0.000 description 5
- 239000000168 bronchodilator agent Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- UHEOYIKQUMWUPY-KWVAZRHASA-N CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)C=O Chemical compound CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)C=O UHEOYIKQUMWUPY-KWVAZRHASA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000000087 stabilizing effect Effects 0.000 description 4
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 239000004813 Perfluoroalkoxy alkane Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000004404 adrenal cortex Anatomy 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229920000840 ethylene tetrafluoroethylene copolymer Polymers 0.000 description 2
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- CRSOQBOWXPBRES-UHFFFAOYSA-N neopentane Chemical compound CC(C)(C)C CRSOQBOWXPBRES-UHFFFAOYSA-N 0.000 description 2
- 229910052755 nonmetal Inorganic materials 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- GTLACDSXYULKMZ-UHFFFAOYSA-N pentafluoroethane Chemical compound FC(F)C(F)(F)F GTLACDSXYULKMZ-UHFFFAOYSA-N 0.000 description 2
- 229920011301 perfluoro alkoxyl alkane Polymers 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical group C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- NPNPZTNLOVBDOC-UHFFFAOYSA-N 1,1-difluoroethane Chemical compound CC(F)F NPNPZTNLOVBDOC-UHFFFAOYSA-N 0.000 description 1
- 229940051271 1,1-difluoroethane Drugs 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000012443 analytical study Methods 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 229960003060 bambuterol Drugs 0.000 description 1
- ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 description 1
- 229960004620 bitolterol Drugs 0.000 description 1
- FZGVEKPRDOIXJY-UHFFFAOYSA-N bitolterol Chemical compound C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)CNC(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 FZGVEKPRDOIXJY-UHFFFAOYSA-N 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960001117 clenbuterol Drugs 0.000 description 1
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002788 crimping Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- QHSJIZLJUFMIFP-UHFFFAOYSA-N ethene;1,1,2,2-tetrafluoroethene Chemical group C=C.FC(F)=C(F)F QHSJIZLJUFMIFP-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- SYCWERNQGSKYAG-QVRIGTRMSA-N hydron;8-hydroxy-5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1h-quinolin-2-one;chloride Chemical compound Cl.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 SYCWERNQGSKYAG-QVRIGTRMSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 229910001867 inorganic solvent Inorganic materials 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical class CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- BCCOBQSFUDVTJQ-UHFFFAOYSA-N octafluorocyclobutane Chemical compound FC1(F)C(F)(F)C(F)(F)C1(F)F BCCOBQSFUDVTJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019407 octafluorocyclobutane Nutrition 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 1
- 229960000797 oxitropium Drugs 0.000 description 1
- 229960004692 perflenapent Drugs 0.000 description 1
- KAVGMUDTWQVPDF-UHFFFAOYSA-N perflubutane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F KAVGMUDTWQVPDF-UHFFFAOYSA-N 0.000 description 1
- 229950003332 perflubutane Drugs 0.000 description 1
- NJCBUSHGCBERSK-UHFFFAOYSA-N perfluoropentane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F NJCBUSHGCBERSK-UHFFFAOYSA-N 0.000 description 1
- 229960004065 perflutren Drugs 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000006223 plastic coating Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229960002288 procaterol Drugs 0.000 description 1
- FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Description
DEGRADATION-RESISTANT GLUCOCORTICOSTEROID
FORMULATIONS
BACKGROUND OF THE INVENTION
Field of the Invention
The invention relates to novel pharmaceutical formulations containing a glucocorticosteroid.
Summary of the Related Art
Glucocorticosteroids, and pharmaceutical formulations thereof, are useful medicaments in the treatment of various ailments including bronchial disorders and inflammatory bowel disorders. However, current formulations of glucocorticosteroids are chemically unstable, resulting in costly and inconvenient storage limitations. The degradation (e.g., oxidation and/or hydrolysis) of glucocorticosteroids, -when in contact with an organic or inorganic solvent, results in chemical instability. Preventing oxidative degradation may be particularly important in enhancing chemical stability to facilitate storage of glucocorticosteroid solutions.
U.S. Patent No. 5,914,122 (Otterbeck etal.) discloses a solution, with a pH of at most 6.0, of a glucocorticosteroids (budesonide) dissolved in a solvent (alcohol, water, or a mixture thereof), which may also include a preservative such as ethylenediamine- tetraacetic acid, cyclodextrins, or a mixture thereof. The preferred concentration of budesonide in the formulations of Otterbeck etal. is between 0.01% and 0.1% by weight (at col. 4, lines 31-33). Otterbeck et l does not disclose a solution of a glucocorticosteroid containing any ingredient other than the preservatives ethylenediamine-tetraacetic acid, cyclodextrins, or a mixture thereof that inhibits degradation of the glucocorticosteroid.
Several investigators have sought to address the issue of the physical and
chemical instability of the crystalline form of glucocorticosteroid powder formulations. For example, U.S. Patent No. 5,874,063 (Briggner et al.) discloses a suspension type aerosol formulation in the form of particles comprising a medicament and an excipient, such as a carbohydrate, an amino acid, or an antioxidant. The particles of Briggner et al. are further treated to enhance their stability with a solvent, such as water or an organic solvent (e.g., an alcohol), where the excess solvent is removed from the particles. Briggner et al. is primarily concerned with the stability of the powder form. This patent does not address the degradation of a glucocorticosteroid in a solution or a suspension formulation for administration using a metered dose inhaler ("MDI"). More important, Briggner et al. does not teach or suggest formulations, which are stabilized by the addition of stabilizing moieties.
Similarly, U.S. Patent No. 5,709,884 (Trofast et al.) teaches a process for conditioning of medicament and excipients in a formulation suitable for inhalation. Trofast et al. is primarily concerned with the physical stability of the crystalline form of raw material components to be later formulated in powder form. Hence, Trofast et al. does not teach or suggest formulations, which are chemically stabilized by the addition of stabilizing moieties. This patent does not address the degradation of a glucocorticosteroid in a solution or a suspension formulation for administration using a metered dose inhaler.
Attempts have been made to stabilize solutions of medicaments for use in metered dose inhalers. For example, U.S. Patent No. 5,676,930 (Jager et al) teaches a formulation including a medicament, a hydrofluorocarbon propellant, a cosolvent, and an acid. Jager et al. focuses on the inclusion of an acid to prevent the degradation of a solution of a bronchodilator by hydrolysis and esterification. Jager et al. does not teach the stabilization of a glucocorticosteroid solution by including in the solution an agent for preventing oxidative degradation rather than an acid.
U.S. Patent No. 6,315,985 (Wu et al) teaches stabilizing a solution of a C-17/21 OH 20-ketosteroid, a propellant, and a cosolvent by storing the solution in a container
having a non-metal interior surface. Wu et al. focuses on reducing degradation of a solution by preventing the solution from contacting metal surfaces, rather than by including in the solution agents that inhibit degradation. Wu et al. does not specifically teach stabilizing a glucocorticosteroid solution by including an agent for preventing oxidative degradation in a solution that can then be stored in a metal or non-metal container.
Therefore, there remains a need for more stable glucocorticosteroid formulations that resist degradation, in particular, oxidative degradation, and display improved chemical and physical stability profiles under standard conditions.
SUMMARY OF THE INVENTION
The present invention provides novel pharmaceutical formulations of glucocorticosteroids that resist degradation and display improved chemical and physical stability profiles under standard conditions.
Accordingly, in one aspect, the invention provides a pharmaceutical composition comprising a glucocorticosteroid, a propellant, a cosolvent, and a radical quencher.
In another aspect, the invention provides a pressurized metered dose inhaler comprising a container equipped with a metering valve and containing a pressurized aerosol formulation comprising a glucocorticosteroid, a propellant, a cosolvent, and a radical quencher.
Another aspect of the invention provides a method for the treatment of a bronchial disorder in a mammal by administering a pharmaceutical formulation comprising a glucocorticosteroid, a propellant, a cosolvent, and a radical quencher.
In a different aspect, the invention provides a method for preventing oxidative degradation of an aerosol formulation including a glucocorticosteroid, a propellant, and a cosolvent by introducing a radical quencher to the formulation.
In certain embodiments of any of the aspects of the present invention, the radical quencher is ascorbic acid, ascorbyl palmitate, sodium bisulfite, butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), glutathione, ubiquinone, a carotenoid, or Vitamin E, or a functional equivalent or derivative thereof. In some embodiments, radical quenchers include Vitamin E, ascorbyl palmitate, butylated hydroxyanisole (BHA), and functional equivalents and derivatives thereof.
The glucocorticosteroid included in the various embodiments of the
invention may be budesonide, testosterone, progesterone, estrogen, flunisolide, triamcinolone, beclomethasone, betamethasone, dexamethasone, fluticasone, methylprednisolone, prednisone, hydrocortisone, ciclesonide, mometasone, desonide, or rofleponide. In certain embodiments, the glucocorticosteroid is budesonide.
The propellant included in the various embodiments are 1,1,1,2- tetrafluoroethane ("HFA-134a"), 1,1,1,2,3,3,3-heptafluoro-n-propane ("HFA- 227ea") or a mixture thereof.
In various embodiments of the above aspects of the invention, the cosolvent is polyol. In certain embodiments, the polyol is a C2-C6 alcohol. In particular embodiments, the polyol is ethanol, isopropanol, or propylene glycol.
In certain embodiments of any of the aspects of the invention, the glucocorticosteroid, propellant, cosolvent, and radical quencher are stored in a container coated with a polymer.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a representation of an HPLC chromatogram of a control formulation (Formulation A) containing budesonide, ethanol, and HFA-134a, but lacking a radical quencher according to the invention, which was stored at 40°C for 28 days.
Figure 2 is a representation of a sample HPLC chromatogram of a representative formulation of the invention containing budesonide, ethanol, HFA- 134a, and ascorbyl palmitate as a radical quencher, which was stored at 40°C for 28 days.
Figure 3 is a graphic representation displaying the total percent degradation of
Formulations A and B in coated and uncoated canisters (AU= Formulation A/uncoated, BU= Formulation B/uncoated, AC= Formulation A/coated, and BC= Formulation B/coated) over a period of 0 - 180 days at 40°C of oven treatment.
DETAILED DESCRIPTION
The patent and scientific literature referred to herein established the knowledge that is available to those with skill in the art. The issued U.S. patents, allowed patent application, and articles cited herein are hereby incorporated in their entirety.
The inventors have made the unexpected discovery that the addition of a radical quencher results in a formulation that resists degradation and displays improved chemical and physical stability profiles under standard conditions.
This discovery has been exploited to provide the present invention, which provides chemically and physically stable formulations of glucocorticosteroids (such as, for example, budesonide) obtained by formulating the glucocorticosteroid with a cosolvent (such as ethanol), a propellant (such as HFA-134a, HFA-227ea, or both), and a radical quencher (such as ascorbyl palmitate), where the glucocorticosteroid remains chemically and physically stable under standard conditions.
Accordingly, in one aspect, the invention provides a pharmaceutical composition which remains chemically and physically stable under standard conditions comprising a glucocorticosteroid, a propellant, a cosolvent, and a radical quencher.
In another aspect, the invention provides a pressurized metered dose inhaler comprising a container equipped with a metering valve and containing a pressurized aerosol formulation comprising a glucocorticosteroid, a propellant, a cosolvent, and a radical quencher.
A different aspect of the invention provides a method for the treatment of a bronchial disorder in a mammal by administering a pharmaceutical formulation
comprising a glucocorticosteroid, a propellant, a cosolvent, and a radical quencher.
In yet another aspect, the invention provides a method for preventing oxidative degradation of an aerosol formulation including a glucocorticosteroid, a propellant, and a cosolvent by introducing a radical quencher to the formulation.
Technical and scientific terms used herein have the meaning commonly understood by one of skill in the art to which the present invention pertains, unless defined otherwise. Reference is made herein to various methodologies and materials known to those of skill in the art. Standard reference works setting forth the general principles of pharmacology include Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9lh Ed., McGraw Hill
Companies Inc., New York (1996). Standard reference works setting forth the general principles of pharmaceutical formulations include Remington's Pharmaceutical Sciences, 181 Ed., Gennaro, Mack Publishing Co., Easton, PA (1990) and Remington: The Science and Practice of Pharmacy, Lippincott, Williams & Wilkins (1995). Another standard reference works setting forth inhalation technology include the "Pharmaceutical Inhalation Aerosol Technology", edited by Anthony J. Hickey, Marcel Dekker, Inc., New York, N.Y. (1992).
Any suitable materials and/or methods known to those of skill can be utilized in carrying out the present invention. However, exemplary materials and methods are described. Materials, reagents and the like to which reference is made in the following description and examples are obtainable from commercial sources, unless otherwise noted.
The methods of the present invention are intended for use with any "mammal" which may experience the benefits of the methods of the invention.
Foremost among such mammals are humans, although the invention is not
intended to be so limited. . A "mammal" also includes animals, and is applicable to veterinary uses.
A "functional equivalent" of a biochemical moiety, is a molecule that possesses a biological activity (either functional or structural) that is substantially similar to a biological activity for the moiety of which it is said to be a functional equivalent. The term "functional equivalent" also includes the functional derivatives of any given glucocorticosteroid and modifications for the performance of a specific function. Accordingly, for example, a functional equivalent may contain additional chemical moieties not normally a part of the molecule to which it is a functional equivalent. Such moieties can improve the molecule's solubility, absorption, biological half-life, pharmacokinetic absorption and adsorption, and the like. The moieties can alternatively decrease the toxicity of the molecule, eliminate or attenuate any undesirable side effect of the molecule, and the like. Moieties capable of mediating such effects are disclosed in Remington's Pharmaceutical Sciences (see supra). Procedures for coupling such moieties to a molecule are well known in the art.
The term "functional derivative" is intended to include chemical derivatives of a molecule having the same function or activity.
"Standard conditions" as used herein denotes 25°C and 60% relative humidity. It has been widely accepted that, for evaluation purposes, incubation for two months at 30°C and 60% relative humidity are intermediate conditions equivalent to exposure for three months at room temperature (30°C/60% relative humidity). Similarly, one month in accelerated conditions at 40°C and 75% relative humidity represents an equivalent exposure for four months at room temperature (25°C/60% relative humidity).
A "container" is a vessel capable of withstanding the vapor pressure of the propellant used such as a plastic-coated glass bottle or aluminum can.
A "pressurized metered dose inhaler" as used herein is designed to deliver a
fixed unit dosage of medicament per actuation or "puff", for example in the range of 10-5000 micrograms of medicament per puff.
A "pressurized aerosol formulation" is a composition or formulation that is adjusted within a container to have a specific vapor pressure which is measured by the units of psi at a certain temperature.
A "metering valve" is designed to deliver a metered amount of the formulation per actuation and incorporate a gasket to prevent leakage of propellant through the valve. Suitable valves are commercially available from manufacturers well known in the aerosol industry.
In accordance with the invention, the term "glucocorticosteroid" refers to a steroid that is either produced by the adrenal-cortex, or is chemically synthesized such that it functionally mimics a steroid produced by the adrenal cortex. A glucocorticosteroid of the invention includes, without limitation, budesonide, testosterone, progesterone, estrogen, flunisolide, triamcinolone, beclomethasone (e.g., as the mono or the dipropionate ester), betamethasone; dexamethasone, fluticasone
(e.g., as the propionate ester), methylprednisolone, prednisone, hydrocortisone, ciclesonide, mometasone, desonide, or rofleponide (i.e., (22R)-6α,9α-difluoro-llβ,21- dihydroxy-16α,17α-propylmethylenedioxy-4-pregnen-3,20-dione), and functional equivalents and functional derivatives thereof. Particular compositions of the invention comprise budesonide.
The amount of glucocorticosteroid utilized in the present formulations is usually from about 0.01% to about 1% by weight, from about 0.05% to about 0.5 % by weight, or about 0.3% by weight, based on the total weight of the aerosol formulation. All weight percentages described herein are based on the total weight of the formulation unless stated otherwise.
A "bronchial disorder" is used to encompass an inflammation or obstruction
of the bronchi, bronchioles, and lung.
The present invention also includes formulations containing non-steroidal bronchodilators. By "bronchodilator" is meant a medicament or drug that relaxes bronchial muscle resulting in expansion of the bronchial air passages. Included as non- glucocorticosteroid bronchodilators are, without limitation, β2-adrenergic agonists, such as albuterol, bambuterol, terbutaline, fenoterol, clenbuterol, procaterol, bitolterol, and brodxaterol; anticholinergic bronchodilators, such as ipratropium bromide and oxytropium bromide. Other non-glucocorticosteroid bronchodilators include formoterol, salmeterol, and TA 2005 (i.e., 8-hydroxy-5-(l-hyroxy-2-2((2-(4- methoxyphenyl)-l-methylethyl)amino)ethyl)-2(lH)-quinolinone) (e.g., as the monohydrochloride), as well as anti-histamines (e.g., terfenadine). One of skill in the art of pulmonary pharmaceuticals will appreciate that the bronchodilators described herein include also functional equivalents and/or derivatives thereof.
In accordance with the invention, a "radical quencher" is used to mean a substance capable of inhibiting radical formation, either by reducing radicals already formed or by preventing radical formation. Numerous radical quenchers are known and include, without limitation, ascorbic acid, ascorbyl palmitate, sodium bisulfite, butylated hydroxy toluene (BHT), butylated hydroxyanisole (BHA), glutathione, ubiquinone, carotenoids and Vitamin E as well as functional equivalents and/or derivatives thereof. As used herein, references to particular radical quenchers, such as, for example, ascorbyl palmitate or butylated hydroxyanisole (BHA), are intended to encompass functional equivalents and derivatives of those radical quenchers. By "radical formation" is meant the process by which a free radical is formed by oxidation and/or oxidative processe(s).
Accordingly, the pharmaceutical compositions of the invention are less prone to oxidative degradation than the counterpart composition lacking the radical quencher according to the invention. Physically and chemically more stable formulations have a considerably longer shelf life, thereby reducing their production
cost and making these formulations more affordable in a world where healthcare expenditures are capped. In addition to the economic advantages, the superior formulations of the invention remain stable at the range of temperatures to which these type of medications are exposed on a daily basis by the average patient. Medicaments are generally kept with the patient during the day and are often exposed to extreme low temperatures (e.g., a cold Boston day) or extreme high temperatures and humidity (e.g., a July day in Miami).
One of ordinary skill in the art can easily determine the presence of oxidative degradation products, for example, by HPLC analysis. For example, the glucocorticosteroid budesonide, 21-dehydrobudesonide is a readily recognizable degradation product of budesonide (see drug master file for budesonide available from the raw material manufacturer Industriale Chimica d.r.l. & Sicor S.p.A.).
In particular embodiments of all of the aspects of the invention, the radical quencher is Vitamin E, ascorbyl palmitate, butylated hydroxyanisole (BHA), or a functional equivalent or derivative thereof.
In accordance with the invention, any fluoroalkane propellant that is suitable for inhalation can be used. Examples of suitable fluoroalkanes (hydrofluoroalkanes) include, without limitation, 1,1,1,2 tetrafluoroethane ("HFA-134a"), 1,1,1,2,3,3,3 heptafluoropropane ("HFA-227ea"), pentafluoroethane ("HFA-125"), 1,1- difluoroethane ("HFA-152a"), and difluorσmethane ("HFA-32"). Hydrocarbon and/or aliphatic gases may be added to modify propellant characteristics as required. Preferably, the aerosol formulation is substantially free of chlorofluorocarbons, which, unlike hydrofluoroalkanes, have been implicated in the depletion of the ozone layer. (For a general discussion, see the Montreal Protocol on Substances that Deplete the Ozone Layer published by the Liaison Office of the United Nations Environmental
Program, New York, NY (1989)). However, if desired, chlorofluorocarbons can be utilized. The fluoroalkane may be 1,1,1,2-tetrafluoroethane (HFA-134a) or 1,1, 1,2,3,3, 3-heptafluoropropane (HFA-227ea). It is understood that the nature of the
propellant used is not an essential element of the invention. Hence, although at the present time HFA's are useful propellants, other can be used in their place without affecting the basic formulation approach described herein.
In various embodiments of all of the aspects of the invention, the propellant is 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoro-n-propane, or a mixture thereof.
The propellant is usually present in an amount of from about 60% to about 97% by weight, or from about 70 to about 90% by weight, based on the total weight of the aerosol formulation.
In accordance with the invention, any cosolvent that is suitable for inhalation and capable of dissolving or solubilizing the glucocorticosteroid in the mixture of cosolvent and propellant can be used. Examples of suitable cosolvents include alcohols, ethers, hydrocarbons, and perfluorocarbons. In some embodiments, the cosolvent is a short chain polar alcohol. In particular embodiments, the cosolvent is an aliphatic alcohol having from one to six carbon atoms, such as ethanol or isopropanol. A useful cosolvent is ethanol. Examples of suitable hydrocarbons include n-butane, isobutane, pentane, neopentane and isopentanes. Examples of suitable ethers include dimethyl ether and diethyl ether. Examples of suitable perfluorocarbons include perfluoropropane, perfluorobutane, perfluorocyclobutane, and perfluoropentane.
In various embodiments of all of the aspects of the invention, the cosolvent is an alcohol. In certain embodiments, the alcohol is a C2-C6 alcohol. In certain embodiments, the alcohol is, without limitation, ethanol, isopropanol, or propylene glycol.
In one non-limiting example, ethanol is utilized as a cosolvent. When ethanol is utilized as the cosolvent, the cosolvent is usually present in an amount of from about
0.01% to about 40%, or from about 3% to about 25% by weight, based on the total weight of the aerosol formulation. The cosolvent (e.g., ethanol) should be present in
an amount which fully dissolves or solubilizes the glucocorticosteroid in the mixture of ethanol and propellant. The cosolvent may be present in amount sufficient to fully maintain the glucocorticosteroid in solution at freezing temperatures, such as 0°C. In general, as the temperature is decreased, the solubility of glucocorticosteroid in the cosolvent is decreased. Therefore, an excess of cosolvent (e.g., ethanol) over the amount required to fully dissolve or solubilize the glucocorticosteroid at ambient or room temperature is useful. In this regard, where the cosolvent is ethanol, the cosolvent is may be present in an amount of at least 10% by weight, at least 15% by weight, at least 20% by weight, or at least 25% by weight. Based on the disclosure provided herein, one skilled in the art will recognize that lower concentrations of medicament usually require lower concentrations of cosolvent, and vice versa, in order to form a stable solution. . Furthermore, one skilled in the art will recognize that the type of propellant utilized can also affect the amount of cosolvent required to fully dissolve or solubilize the glucocorticosteroid in the mixture of cosolvent and propellant.
In general, the greater the polarity of the propellant the less cosolvent required to fully dissolve or solubilize the glucocorticosteroid. For example, when HFA-134a is utilized as the propellant and ethanol is utilized as the cosolvent in a formulation of the invention, the amount of ethanol is from about 10% to about 30% by weight. When HFA-227ea is utilized as the propellant and ethanol is utilized as the cosolvent in a formulation of the invention, the amount of ethanol is from about 6% to about 20% by weight.
One formulation of the invention comprises as a propellant, either HFA-134a or HFA-227ea in an amount less than about 90% by weight; as a cosolvent, ethanol in an amount of at least about 10% by weight; as a glucocorticosteroid, budesonide in an amount of from about 0.05% to about 0.5% by weight; and as a radical quencher, either Vitamin E, ascorbyl palmitate, BHA, or a functional equivalent or derivative thereof in an amount of from about 0.01% to about 1% by weight. One formulation
comprises about 86% by weight of HFA-227ea, about 14% by weight of ethanol, and about 0.3% by weight of budesonide. Another formulation comprises about 75% by weight of HFA-134a, about 25% by weight of ethanol, and about 0.3% by weight of budesonide.
Pressurized metered dose inhalers are well known in the art and are useful for administering a formulation of the invention, where the formulation of the invention is an aerosol formulation. Any pressurized metered dose inhaler that is suitable for application of medicaments to the lungs or nose of a patient can be used. Pressurized metered dose inhalers usually are equipped with an actuator having a spray orifice diameter of about 460/xm. However, with the higher concentrations of solvent employed in the present invention, it may be desirable that the solvent evaporates as soon as possible after inhalation. This can be achieved by reducing particle size by reducing the spray orifice diameter, for example, to 250 μm, in combination with using solvent concentrations greater than about 10% by weight.
Based on the disclosure provided herein, one skilled in the art will be able to adjust the component composition to deliver a desired dose for the selected metered valve, without undue experimentation. For example, the composition may be altered to adjust the vapor pressure of the formulation. The aerosol formulation and metering valve are usually selected to provide a therapeutically effective amount of the budesonide per actuation. An example of a therapeutically effective amount of budesonide is about 50 μg to about 400 μg per activation, or about 100 μg to about 250 μg per activation.
The pressurized metered dose inhaler can be formed by any suitable method. For example, the selected amount of budesonide can be weighed and inserted into a suitable container, such as a glass bottle or aluminum canister. The use of containers coated with a polymer has been found to confer a limited additional protection of the formulation as evidenced by the reduction of the oxidative degradation products observed. Various polymers are known in the art for coating the interior of drug
formulation containers (see, e.g., U.S. Patent No. 6,315,985). Nonlimiting examples of useful polymers include polytetrafluoroethylene (PTFE), perfluoroethylenepropylene (FEP), perfluoroalkoxyalkane (PFA), and ethylene tetrafluoroethylene (ETFE). The cosolvent can then be weighed and added to the container. Once all of the non-gaseous components have been added to the container, the metered valve can be crimped on to seal the container. Then, the desired amount of propellant can be added to the container through the metered valve. The budesonide can be dissolved or solubilized into the mixture of cosolvent and propellant by agitating the formulation, such as by sonication. For the small scale preparations, about 5 minutes of sonication has been found to be suitable to dissolve or solubilize a formulation having a total weight of about 12 grams. Alternative well known methods of homogenizing the formulation of the invention may be substituted on a commercial scale production.
The elements in all of the aspects of the present inventions are essentially as set forth in one aspect of the invention. In that aspect, the invention provides a pharmaceutical composition which remains chemically and physically stable under standard conditions comprising any glucocorticosteroid (e.g., budesonide), any propellant (e.g., fluoroalkane propellant - 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoro-n-propane or a mixture thereof), any cosolvent (e.g., alcohols, ethers, hydrocarbons, and perfluorocarbons), and any radical quencher (e.g., Vitamin E, ascorbyl palmitate, BHA, or a functional equivalent or derivative thereof).
The following examples are intended to further illustrate certain embodiments of the invention and are not limiting in nature. Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific substances and procedures described herein. Such equivalents are considered to be within the scope of this invention, and are covered by the following examples and claims.
Example I
Degradation-Resistance of a Glucocorticosteroid in a Formulation of the
Invention
Laboratory formulations according to the present invention were generated by combining the components shown in Tables I and V, utilizing a series of steps. The initial step involves separately adding each component of the formulation within a bottle or canister. The first steps include: adding weighed the glucocorticosteroid into a glass bottle or an aluminum canister which may or may not be coated with a plastic coating, adding the weighed radical quencher to the bottle or canister, and adding the weighed cosolvent to the bottle or canister. The following step involves crimping a valve upon the bottle or canister. Next, the step of sonicating the formulating for approximately two minutes. Finally, the step of adding a known amount of propellant through the valve into the bottle or canister and sonicating the formulation for approximately two minutes. Note that the balance is preferably tared
I with the canister between subsequent additions of an ingredient.
Ascorbyl Palmitate as the Radical Quencher
Using ascorbyl palmitate as the radical quencher, budesonide as the glucocorticosteroid, ethanol as the cosolvent, and HFA-134a as the propellant, two formulations (A and B) were made in canisters that were either coated or uncoated with a polymer on the interior wall. The components of the Formulations A and B are shown in Table I.
Table I Formulations A and B
Formulations A and B were subjected to stability study conditions of 40°C in a laboratory oven. At various time points, formulation samples were tested for average shot weight (mg), dose delivered/actuation (μg/actuation), percentage of total epimers of budesonide (R and S), and percentage material balance based on shot weights. The material balance indicates the total percentage of drug recovered from the valve stem, actuator, and dose tube used in Dose Uniformity Testing.
The results of these stability studies for 7, 28, 63, 92 and 180 days on Formulation A are shown in Table II (in the uncoated canister) and Table III (coated canister). Table IV shows a comparison of the total impurities (identified and unknown) after 7, 28, 63, 92 and 180 days of stability study conditions on Formulation A from uncoated and coated canisters.
Table II Stability of Formulation A in Uncoated Container
Table III Stability of Formulation A in Coated Canisters
Table IV Degradation Profile of Formulation A in Coated and Uncoated Canisters
The results of these stability studies for 7, 28, 63, 92 and 180 days on Formulation B (prepared in uncoated and coated aluminum canisters) are shown in Tables V and VI, respectively. Table VII shows a comparison of the total impurities (identified and unknown) after 7, 28, 63, 92 and 180 days of stability study conditions on Formulation B from uncoated and coated canisters.
* t &;;« P& ;;.:& u
Table V Stability of Formulation B Uncoated
Table VI Stability of Formulation B Coated
Table VII
Degradation Profile of Formulation B in Coated and Uncoated Canister
Studies after 14 days of exposure to 40°C did not exhibit degradation products in both the control formulation (Formulation A) and the formulation containing the radial quencher (Formulation B). Moreover, after 28 days of treatment at 40°C, Formulation B exhibited an average material balance of 100.56% (average of 101.57% in uncoated canister and 99.55% in coated canister). Control Formulation A containing no radical quencher showed an average material balance of 106.96% after 28 days (average of 105.96% in uncoated canister and 107.96% in coated canister).
Surprisingly, no degradation products were observed in Formulation B after 28 days of oven treatment at 40°C compared with 2.17% total degradation products (both 21-Dehydro budesonide and an unknown impurity) observed in the control formulation (Formulation A).
This difference in the extent of degradation observed for Formulation A and Formulation B after 28 days at 40°C is illustrated in Figures 1 and 2 respectively. In the HPLC chromatogram of Figure 1, the pure, non-degraded product eluted as two
completely resolved peaks of the isomers (R and S) at approximately 19-23 minutes after injection. The two peaks corresponding to the R and the S isomer of the degradation product, 21-Dehydrobudesonide, appeared at approximately 12-14 minutes after injection. In the HPLC chromatogram of Figure 2, the pure, non-degraded product eluted as two completely resolved peaks of the isomers (R and S) at approximately 19-23 minutes after injection. Notably absent are the two peaks corresponding to the R and the S isomer of the degradation product, 21- Dehydrobudesonide normally eluting at approximately 12-14 minutes after injection.
Moreover, even after 180 days of 40°C oven treatment, the total percent degradation exhibited by Formulation B, containing the radical quencher, was only
0.61 and 1.00 in both uncoated and coated canisters, respectively. Comparatively, the total percent degradation observed from Formulation A, containing no radical quencher, was 14.20 and 4.88 in both uncoated and coated canisters, respectively. This remarkable difference in percent degradation observed is graphically shown in Figure 3 (see graph below). Figure 3 shows the percent total degradation of the various formulations on coated versus uncoated canisters (AU= Formulation A in an uncoated canister; BU= Formulation B in an uncoated canister; AC = Formulation A in a coated canister; BC= Formulation B in a coated canister.)
Other formulations
Based on successful preformulation studies using ascorbyl palmitate and Vitamin E-acetate (data not shown), other formulations containing these radical quenchers were also prepared with HFA-134a, HFA-227ea, or a combination of both propellants, as described in Table VIII. Representative glucocorticosteroidical formulations containing HFA and either ascorbyl paltiate or Vitamin E - acetate are tabulated hereafter.
Table VIII Representative Stabilized Formulations Containing HFA Propellant(s)
* HFA-Propellant included HFA-134a, HFA-227ea, or a combination of both.
Analytical studies of these formulations as compared to control formulations (all ingredients are identical except for the absence of the radical quencher) following a stress treatment (14 days at 40°c) showed a significant reduction of degradation in the presence of a radical quencher (data not shown).
Similar results were obtained when using USP intentional degradation methodologies (such as acid, base, peroxide) (data not shown).
Example II Use of Representative Formulations for Aerosol Delivery
To illustrate the use of radical quencher-containing formulations according to the invention, representative formulation B is administered to patients in need of budesonide regimens. One of skill in the art will appreciate that while this example is written for the administration of a budesonide- containing formulation, similar formulations containing other glucocorticosteroids -as discussed in more detail above — may be easily formulated and administered as described herein and according to standard methodologies known in the field. Similarly, while this example is written for a formulation of a 100 /.g/ or 200/-g/ actuation budesonide-HFA solution containing a radical quencher, different concentrations, delivery dosages and forms may be easily tailored to meet a specific medical condition or a particular patient's requirement (s).
Patients suffering from a bronchial disorder such as asthma are orally administered Formulation B (see above) two puffs twice a day (200 μg/ actuation or 100 j g/ actuation depending on the severity of the patient's conditions). Improvement in asthma control following inhaled administration of Formulation B is expected to occur within 24 hours of beginning treatment although, maximum benefit may not be achieved for one to two weeks or longer after starting treatment. After asthma stability has been achieved the starting dose it is always desirable to titrate to the lowest effective dose to reduce the possibility of side effects.
Example HI Comparison of Radical Quenchers
To compare the effectiveness of various radical quenchers in preventing degradation of budesonide formulations, formulations containing budesonide, HFA-134a, ethanol, and a radical quencher were made in uncoated canisters using the steps described in Example I. The compositions of the formulations are shown in Table IX. Formulations were made containing each radical quencher with and without 3% aqueous hydrogen peroxide. The hydrogen peroxide was included in some formulations to challenge the radical quencher.
Table IX Formulations Containing a Radical Quencher
The initial impurities in each formulation were measured, and the formulations were stored at 40° C and 75% relative humidity. Impurities were measured again after 4 weeks and after 3 months. For selected formulations, impurities were also measured after 11 months. Comparisons of the percent by weight of impurities in the formulations initially and at each time point are presented in Tables X, XI, and XII. Chromatograms used to measure impurities showed degradation products associated with oxidative and aqueous degradation, but not acidic or basic degradation.
Table X Comparison of Impurities After 4 Weeks
Table X (Continued)
Table XI Comparison of Impurities After 3 Months
Table XI (Continued)
Table XII Comparison of Impurities After 11 Months
Tables X-XII demonstrate that butylated hydroxyanisole (BHA) and ascorbyl palmitate were very effective in reducing degradation of the budesonide formulations. Vitamin E also effectively reduced degradation. Stable formulations for metered dose inhalers (MDIs) including Vitamin E or a functional equivalent or derivative of BHA or ascorbyl palmitate are particularly useful, as inhalation of BHA presents safety concerns and formulations including ascorbyl palmitate tended to form clumps of solid matter that might impede MDI operation. Solutions including ascorbyl palmitate along with a means for reducing clumping are also useful in MDIs.
While the claimed invention has been described in detail and with reference to
specific embodiments thereof, it will be apparent to one of ordinary skill in the art that various changes and modifications can be made to the claimed invention without departing from the spirit and scope thereof.
Claims (52)
1. A pharmaceutical composition comprising a glucocorticosteroid, a propellant, a cosolvent, and a radical quencher.
2. The pharmaceutical composition of Claim 1, wherein the radical quencher is Vitamin E.
3. The pharmaceutical composition of Claim 1, wherein the radical quencher is Vitamin E acetate.
4. The pharmaceutical composition of Claim 1, wherein the radical quencher is ascorbyl palmitate.
5. The pharmaceutical composition of Claim 1, wherein the radical quencher is butylated hydroxyanisole (BHA).
6. The pharmaceutical composition of Claim 1, wherein the radical quencher is selected from the group consisting of ascorbic acid, ascorbyl palmitate, sodium bisulfite, butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), glutathione, ubiquinone, carotenoids, Vitamin E, and functional equivalents and/or derivatives thereof.
7. The pharmaceutical composition of Claim 1, wherein the glucocorticosteroid is selected from the group consisting of budesonide, testosterone, progesterone, estrogen, flunisolide, triamcinolone, beclomethasone, betamethasone, dexamethasone, fluticasone, methylprednisolone, prednisone, hydrocortisone, ciclesonide, mometasone, desonide, and rofleponide.
8. The pharmaceutical composition of Claim 1, wherein the glucocorticosteroid is budesonide.
9. ' The pharmaceutical composition of Claim 1, wherein the propellant is 1,1,1,2- tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoro-n-propane, or a mixture thereof.
10. The pharmaceutical composition of Claim 1, wherein the cosolvent is a polyol.
11. The pharmaceutical composition of Claim 10, wherein the polyol is a C2-C6 alcohol.
12. The pharmaceutical composition of Claim 10, wherein the polyol is selected from the group consisting of ethanol, isopropanol, and propylene glycol.
13. The pharmaceutical composition of Claim 1, wherein the pharmaceutical composition is stored in a container coated with a polymer.
14. A pressurized metered dose inhaler comprising a container equipped with a metering valve and containing a pressurized aerosol formulation comprising a glucocorticosteroid, a propellant, a cosolvent, and a radical quencher.
15. The pressurized metered dose inhaler according to Claim 14, wherein the glucocorticosteroid is selected from the group consisting of budesonide, testosterone, progesterone, estrogen, flunisolide, triamcinolone, beclomethasone, betamethasone, dexamethasone, fluticasone, methylprednisolone, prednisone, hydrocortisone, ciclesonide, mometasone, desonide, and rofleponide.
16. The pressurized metered dose inhaler according to Claim 14, wherein the glucocorticosteroid is budesonide.
17. The pressurized metered dose inhaler according to Claim 14, wherein the propellant is 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoro-n-propane, or a mixture thereof.
18. The pressurized metered dose inhaler according to Claim 14, wherein the cosolvent is a polyol.
19. The pressurized metered dose inhaler according to Claim 18, wherein the polyol is a C2-C6 alcohol.
20. The pressurized metered dose inhaler according to Claim 18, wherein the polyol is selected from the group consisting of ethanol, isopropanol, and propylene glycol.
21. The pressurized metered dose inhaler according to Claim 14, wherein the radical quencher is Vitamin E.
22. The pressurized metered dose inhaler according to Claim 14, wherein the radical quencher is Vitamin E acetate.
23. The pressurized metered dose inhaler according to Claim 14, wherein the radical quencher is ascorbyl palmitate.
24. The pressurized metered dose inhaler according to Claim 14, wherein the radical quencher is butylated hydroxyanisole (BHA).
25. The pressurized metered dose inhaler according to Claim 14, wherein the radical quencher is selected from the group consisting of ascorbic acid, ascorbyl palmitate, sodium bisulfite, butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), glutathione, ubiquinone, carotenoids, Vitamin E, and functional equivalents and/or derivatives thereof.
26. The pressurized metered dose inhaler according to Claim 14, wherein the interior of the container is coated with a polymer.
27. A method for the treatment of a bronchial disorder in a mammal by administering a pharmaceutical formulation comprising a glucocorticosteroid, a propellant, a cosolvent, and a radical quencher.
28. The method according to Claim 27, wherein the glucocorticosteroid is selected from the group consisting of budesonide, testosterone, progesterone, estrogen, flunisolide, triamcinolone, beclomethasone, betamethasone, dexamethasone, fluticasone, methylprednisolone, prednisone, hydrocortisone, ciclesonide, mometasone, desonide, and rofleponide.
29. The method according to Claim 27, wherein the glucocorticosteroid is budesonide.
30. The method according to Claim 27, wherein the propellant is 1,1,1,2- tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoro-n-propane, or a mixture thereof.
31. The method according to Claim 27, wherein the cosolvent is a polyol.
32. The method according to Claim 31, wherein the polyol is a C2-C6 alcohol.
33. The method according to Claim 31, wherein the polyol is selected from the group consisting of ethanol, isopropanol, and propylene glycol.
34. The method according to Claim 27, wherein the radical quencher is Vitamin E.
35. The method according to Claim 27, wherein the radical quencher is Vitamin E acetate.
36. The method according to Claim 27, wherein the radical quencher is ascorbyl palmitate.
37. The method according to Claim 27, wherein the radical quencher is butylated hydroxyanisole (BHA).
38. The method according to Claim 27, wherein the radical quencher is selected from the group consisting of ascorbic acid, ascorbyl palmitate, sodium bisulfite, butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), glutathione, ubiquinone, carotenoids, Vitamin E, and functional equivalents and/or derivatives thereof.
39. The method according to Claim 27, wherein the pharmaceutical formulation is stored in a container coated with a polymer.
40. A method for preventing oxidative degradation of an aerosol formulation including a glucocorticosteroid, a propellant, and a cosolvent, the method comprising introducing a radical quencher to the formulation.
41. The method according to Claim 40, wherein the glucocorticosteroid is selected from the group consisting of budesonide, testosterone, progesterone, estrogen, flunisolide, triamcinolone, beclomethasone, betamethasone, dexamethasone, fluticasone, methylprednisolone, prednisone, hydrocortisone, ciclesonide, mometasone, desonide, and rofleponide.
42. The method according to Claim 40, wherein the glucocorticosteroid is budesonide.
43. The method according to Claim 40, wherein the propellant is 1,1,1,2- tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoro-n-propane, or a mixture thereof.
44. The method according to Claim 40, wherein the cosolvent is a polyol.
45. The method according to Claim 44, wherein the polyol is a C2-C6 alcohol.
46. The method according to Claim 44, wherein the polyol is selected from the group consisting of ethanol, isopropanol, and propylene glycol.
47. The method according to Claim 40, wherein the radical quencher is Vitamin E.
48. The method according to Claim 40, wherein the radical quencher is Vitamin E acetate.
49. The method according to Claim 40, wherein the radical quencher is ascorbyl palmitate.
50. The method according to Claim 40, wherein the radical quencher is butylated hydroxyanisole (BHA).
51. The method according to Claim 40, wherein the radical quencher is selected from the group consisting of ascorbic acid, ascorbyl palmitate, sodium bisulfite, butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), glutathione, ubiquinone, carotenoids, Vitamin E, and functional equivalents and/or derivatives thereof.
52. The method according to Claim 40, further comprising storing the aerosol formulation in a container coated with a polymer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/768,915 | 2001-01-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002245329A1 true AU2002245329A1 (en) | 2002-08-06 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4777560B2 (en) | Steroid solution aerosol products with enhanced chemical stability | |
US10668018B2 (en) | Pharmaceutical compositions | |
US20030113268A1 (en) | Degradation-resistant glucocorticosteroid formulations | |
JP6931383B2 (en) | Pharmaceutical composition | |
AU776257B2 (en) | Pharmaceutical aerosol formulations containing fluoroalkanes, budesonide and formoterol | |
AU2002313828B2 (en) | Pharmaceutical compositions for the treatment of asthma | |
EP2223682A1 (en) | Stable pharmaceutical solution formulations for pressurised metered dose inhalers | |
UA123919C2 (en) | Pharmaceutical composition | |
JP2020073516A5 (en) | ||
US6068832A (en) | Chlorofluorocarbon-free mometasone furoate aerosol formulations | |
JP2012197306A (en) | Use of ciclesonide for treatment of respiratory disease | |
AU719079B2 (en) | Chlorofluorocarbon-free mometasone furoate aerosol formulations | |
US20050095206A1 (en) | Aerosol pharmaceutical solution formulation containing glucocorticoids stable to the storage; method for stabilizing formulations and use of a stabilizer | |
WO2002058705A2 (en) | Degradation-resistant glucocorticosteroid formulations | |
JP2007533706A (en) | Use of ciclesonide for the treatment of respiratory diseases in smoking patients | |
AU2002245329A1 (en) | Degradation-resistant glucocorticosteroid formulations | |
MXPA04008409A (en) | An aerosol pharmaceutical solution formulation suitable for oral or nasal inhalation containing glucocorticoids stable to the storage; method for stabilizing formulations and use of a stabilizer. | |
MXPA01006082A (en) | Pharmaceutical aerosol formulations containing fluoroalkanes, budesonide and formoterol | |
MXPA01006083A (en) | Pharmaceutical aerosol formulations containing fluoroalkanes and budesonide |